Changing bacteriology of abdominal and surgical sepsis

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 590-595

  Chen, Yen Hsu ^a,b   Hsueh, Po Ren ^c  

^a Division of Infectious Diseases   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

antimicrobial susceptibility breakpoint; epidemiology; intra abdominal infection

Indexed keywords

CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; IMIPENEMASE; MEROPENEM; METALLO BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL PERITONITIS; BACTERIOLOGY; BACTERIUM DETECTION; BACTERIUM ISOLATE; BILIARY TRACT INFECTION; CLINICAL LABORATORY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; STANDARD; SURGICAL INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; SEPSIS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84865864098     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835635cb     Document Type: Review

References (51)

1. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133-164.
2. Hsueh PR, Hawkey PM. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia. Int J Antimicrob Agents 2007; 30:129-133.
3. Arpin C, Noury P, Boraud D, et al. Autochthonous case of NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient. Antimicrob Agents Chemother 2012; 56:3432-3534.
4. Lascols C, Hackel M, Marshall SH, et al. Increasing prevalence and dissemination of NDM-1 metallo-b-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011; 66:1992-1997.
5. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-67.
6. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study. Surg Infect (Larchmt) 2010; 11:371-378.
7. Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54:3031-3034.
8. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ. Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America-SMART 2002-2009. J Chemother 2011; 23:266-272.
9. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55:965-973.
10. Hawser S, Hoban D, Bouchillon S, et al. Antimicrobial susceptibility of intraabdominal Gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011; 30:173-179.
11. Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extendedspectrum b-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2012; 18:253-259.
12. Chen YH, Hsueh PR, Badal RE, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011; 62:280-291.
13. Yang Q, Wang H, Chen M, et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2010; 36:507-512.
14. Canton R, Loza E, Aznar J, et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum b-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011; 24:223-232.
15. Brink AJ, Botha RF, Poswa X, et al. Antimicrobial susceptibility of Gramnegative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt) 2012; 13:43-49.
16. Seifert H, Dalhoff A. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010; 65:2405-2410.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing.DocumentM100-S22.Wayne, PA:CLSI.2012.
18. Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011; 55:3917-3921.
19. Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-b-lactamase among Gram-negative bacilli in Latin America: 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis 2011; 15:34-39.
20. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791-1798.
21. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18:263-272.
22. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011; 37:291-295.
23. Jean SS, Hsueh PR, Lee WS, et al. In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme. Eur J Clin Microbiol Infect Dis 2010; 29:471-475.
24. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-b-lactamases: a last frontier for beta-lactams? Lancet Infect Dis 2011; 11:381-393.
25. Ortega M, Marco F, Soriano A, et al. Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother 2012; 67:1508-1513.
26. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61:297-310.
27. Kerdsin A, Dejsirilert S, Sawanpanyalert P, et al. Sepsis and spontaneous bacterial peritonitis in Thailand. Lancet 2011; 378:960.
28. Ariza X, Castellote J, Lora-Tamayo J, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56:825-832.
29. Piroth L, Pechinot A, Minello A, et al. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. Scand J Infect Dis 2009; 41:847-851.
30. Soriano G, Castellote J, Alvarez C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010; 52:39-44.
31. Fierer J, Walls L, Chu P. Recurring Klebsiella pneumoniae pyogenic liver abscesses in a resident of San Diego, California, due to a K1 strain carrying the virulence plasmid. J Clin Microbiol 2011; 49:4371-4373.
32. Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol 2005; 100:322-331.
33. Fang CT, Lai SY, Yi WC, et al. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 2007; 45:284-293.
34. Di Carlo P, Pantuso G, Cusimano A, et al. Two cases of monomicrobial intraabdominal abscesses due to KPC-3 Klebsiella pneumoniae ST258 clone. BMC Gastroenterol 2011; 11:103.
35. Fitzmaurice GJ, McWilliams B, Hurreiz H, Epanomeritakis E. Antibiotics versus appendectomy in the management of acute appendicitis: a review of the current evidence. Can J Surg 2011; 54:307-314.
36. Lamps LW. Infectious causes of appendicitis. Infect Dis Clin North Am 2010; 24:995-1018.
37. Ho PL, Li Z, Lai EL, et al. Emergence of NDM-1-producing Enterobacteriaceae in China. J Antimicrob Chemother 2012; 67:1553-1555.
38. Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012. doi: 10.1093/jac/dks088. [Epub ahead of print]
39. Salabi AE, Toleman MA, Weeks J, et al. First report of the metallo-b-lactamase SPM-1 in Europe. Antimicrob Agents Chemother 2010; 54:582.
40. Cheng NC, Liu CY, Huang YT, et al. In vitro susceptibilities of clinical isolates of ertapenem-nonsusceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam. J Antimicrob Chemother 2012; 67:1413-1421.
41. Toleman MA, Simm AM, Murphy TA, et al. Molecular characterization of SPM-1, a novel metallo-b-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002; 50:673-679.
42. Zavascki AP, Gaspareto PB, Martins AF, et al. Outbreak of carbapenemresistant Pseudomonas aeruginosa producing SPM-1 metallo-b-lactamase in a teaching hospital in southern Brazil. J Antimicrob Chemother 2005; 56:1148-1151.
43. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
44. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-betalactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046-5054.
45. Walsh TR, Toleman MA. The new medical challenge: why NDM-1? Why Indian? Expert Rev Anti Infect Ther 2011; 9:137-141.
46. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355-362.
47. Mataseje LF, Bryce E, Roscoe D, et al. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother 2012; 67:1359-1367.
48. Denis C, Poirel L, Carricajo A, et al. Nosocomial transmission of NDM-1-producing Escherichia coli within a nonendemic area in France. Clin Microbiol Infect 2012; 18:E128-E130.
49. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011; 19:588-595.
50. Kaase M, Nordmann P, Wichelhaus TA, et al. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother 2011; 66: 1260-1262.
51. Nordmann P, Boulanger AE, Poirel L. NDM-4 Metallo-b-lactamase with increased carbapenemase activity from Escherichia coli. Antimicrob Agents Chemother 2012; 56:2184-2186.